Pursuing More Potent and Durable Immune Responses for Cancer
Our approach is anticipated to work in patients with weakened immune systems and facilitate a therapeutic response. We have built a portfolio of immunotherapies which are designed to target a range of tumor types including certain lung, gastric and esophageal cancers. We are also working to develop immunotherapies using our unique approach to target Head & Neck cancers, Lung squamous cell carcinoma and cervical cancer. We believe that targeting tumor cells via recognition of unique HLA-peptide complexes on tumor cells with multi-specific antibodies presents a meaningful opportunity to expand the benefits of immunotherapy to more patients.
Nexoplex is excited to announce that we have partnered with MBC Biolabs, one of the Bay Area’s leading biotech incubators, at their San Carlos location.
With 8-10 applicants for every space that opens and over $20 billion in raised capital, MBC Biolabs has become the most exclusive life science incubator in the Bay Area, offering state-of-the-art facilities, instrumentation, and equipment as well as operational support.
Meet Our Leadership
Nexoplex has assembled a group of distinguished scientific founders and advisers, a highly experienced leadership team, and a seasoned board of directors to tackle fundamental challenges at the intersection of cancer genomics and immunotherapy.
Wayne Robinson
CEO
Wayne is a seasoned financial executive with extensive experience across multinational corporations and global advisory firms. He served as a Partner at PricewaterhouseCoopers and held senior financial leadership roles as SVP Tax and Business Integration at Cardinal Health and Director of Tax at GenCorp, leading global tax strategy and operations.
Rachel Miller
VP of Operations
Previously Director of Marketing Communications at Permission.io, a fintech startup. Rachel also served on TikTok's legal team in the Trust & Safety department. She has significant experience in technology law, management, and business administration.
Venita De Almeida
Venita De Almeida joins Nexoplex Bio as a drug development leader with more than two decades of in-depth oncology research and development experience. Prior to joining Nexoplex bio, she has led multi-disciplinaryteams to advance programs from research to early clinical development and has contributed to over 10 investigational new drug applications for innovative therapeutics across diverse modalities including T cell engagers, antibody-drug conjugates, antibodies and fusion proteins.
Joshua Goldsmith
Joshua Goldsmith joins Nexoplex Bio as an industry leading scientist with over 15 years of drug development experience. In addition to his prior work developing CD3 bispecifics therapeutics for pHLA targets, he has contributed to the filing of 6 INDs across diverse modalities that include multi specific antibodies, effector enhanced IgGs, antibody-drug conjugates, and small molecules for virology and oncology targets.
Alejandro Ramirez
Alejandro “Alex” Ramirez joins Nexoplex Bio as a research director with 12 years of antibody discovery and engineering experience including B cell cloning, antibody library screening via phage and yeast display and antibody optimization. He has experience ranging from early-stage Research and Development (R&D) organizations to large pharmaceutical corporations. He holds expertise in establishing single B cell monoclonal antibody discovery platforms in various animal models.
May Khadilkar
May Khadilkar joins Nexoplex Bio as a scientist with 6 years of research & development experience in immunology & cancer therapeutics. She has significant expertise in discovering and developing next-generation research, managing preclinical studies, and in project management.
Careers
At Nexoplex, we are committed to progressing the field of oncological immunotherapy. We aim to combine novel science with a focus on culture and teamwork, and are looking for passionate, innovative people to join us.
read more